The retinoic-acid-receptor-related orphan receptors (RORs) are members of the nuclear receptor (NR) superfamily whose activity has been implicated in several physiological and pathological processes. The RORs, specifically RORa and RORg, are considered to be master regulators of T H 17 cells, a recently described subset of CD4 + T helper cells that have been demonstrated to have a pathological role in autoimmune disease. As with most members of the NR superfamily, RORs are ligand-regulated, suggesting that their activity can be modulated by synthetic ligands. Recent advances in the field have established that selective inhibition of the RORs is a viable therapeutic approach for not only the treatment of autoimmune disorders but also ROR-mediated metabolic disorders.
Introduction
The human NR superfamily (see Glossary) is a highly conserved family of transcription factors composed of 48 members. NRs function as ligand-dependent transcription factors and share considerable amino acid sequence homology [1] . General structural characteristics of NRs are a variable N-terminal A/B domain, a central, highly conserved DNA-binding domain (DBD, also termed a C region), a hinge region (D), and a C-terminal ligand-binding domain (LBD, or E region). The LBD is responsible for recognition and binding of the receptor ligand as well as for ligand-dependent transcriptional activity. Some receptors contain an additional C-terminal region, or F domain, of which the function is poorly understood.
Approximately half of the NR superfamily have wellcharacterized natural ligands, whereas the remaining receptors are considered to be 'orphan' receptors and remain the focus of intense research [2] . The majority of NRs with identified natural ligands are also validated targets for clinical purposes and are a rich source of therapeutics aimed at the treatment of a great number of diseases, including inflammation, cancer, and metabolic disorders. Orphan NRs are an active area of research due to the potential for identification of ligands that may be used to modulate these receptors with the goal of developing targeted therapeutics for various diseases [3] . Over the past few years there have been significant breakthroughs in the identification of novel ligands, both natural and synthetic, for several orphan NRs. This review examines the progress made in the identification of ligands for the RORs and their roles in immune and metabolic processes.
RORs: the basics
The ROR family comprises three members -RORa (NR1F1), RORb (NR1F2), and RORg (NR1F3). These are considered to be 'orphan' receptors because their endogenous ligands have yet to be agreed upon definitively. Owing to their known roles in metabolic and immune processes, there is significant interest in the identification of ligands that regulate the RORs due to their potential for clinical utilization. Unlike most family members, the RORs recognize and bind as monomers to specific sequences of DNA, termed ROR response elements (ROREs), typically consisting of an AGGTCA 'half site' with a 5 0 AT-rich extension in the regulatory region of the target gene [4] [5] [6] . When bound to this element within the promoters of their target genes, RORs constitutively recruit coactivators, leading to continual activation of transcription of their target genes [7, 8] . Another group of NRs, the REV-ERBs, recognize the same response elements as the RORs and are coexpressed in many tissues [9] [10] [11] . The REV-ERBs are ligand-dependent transcriptional repressors and, in many cases, functionally antagonize the action of the RORs [12] [13] [14] .
The three RORs display significant sequence similarity and conservation between species. Each ROR generates multiple isoforms based on alternative promoter usage and exon splicing, with all of the isoforms varying only in the Nterminal region of the receptor [7] . The RORs display distinct patterns of tissue expression and are involved in the regulation of various physiological processes. RORa is widely expressed and is found in liver, skeletal muscle, skin, lungs, adipose tissue, kidney, thymus, and brain [15, 16] . The expression of RORb is extremely restricted and is limited to the central nervous system [17, 18] . RORgt has been the focus of considerable attention due to its role in T helper 17 cell (T H 17) development and autoimmune disease pathology. RORg, specifically RORg2 (also termed RORgt), is highly expressed in immune tissues, including the thymus, but there is significant expression of RORg in the liver, skeletal muscle, adipose tissue, and kidney [7] . Due to significant sequence and functional similarities, ROR subtypes coexpressed in cells may exhibit functional overlap [7] . However, the physiological relevance and responsiveness of all of the different isoforms of each ROR have yet to be clarified.
ROR regulation in circadian rhythms
Circadian rhythms are daily cycles of biochemical, behavioral, and physiological processes controlled by endogenous 'clocks' that play essential roles in the regulation of the physiology of an organism, including metabolism ( Figure 1 ) [19] . In mammals, the master circadian clock is located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Aberrant circadian rhythms are associated with numerous disorders in humans, including sleep and mood disorders. The circadian rhythm is generated by a feedback loop where heterodimers of BMAL1 and CLOCK (the positive arm) activate the expression of the cryptochrome (Cry) and period (Per) genes (the negative arm). RORa is a core part of the clock machinery that positively regulates the expression of BMAL1 [20, 21] . RORa competes with REV-ERBa for binding to their shared DNA response element in the BMAL1 promoter, resulting in REV-ERBa-mediated repression or RORa-mediated activation of BMAL1 expression [21] [22] [23] . This oscillating expression of RORa and REV-ERBa in the SCN leads to the circadian pattern of BMAL1 expression, thus interconnecting the positive and negative arms of the core circadian clock ( Figure 1 ). Therefore, RORa influences the period length and stability of the clock [20] .
Genetic models in which the RORs are either modified or have been deleted have been instrumental in identifying their roles in the circadian rhythm. The staggerer mouse (RORa sg/sg ) is a natural mouse mutant that carries an intragenic insertion within the RORa gene, and this results in a frameshift and premature stop codon, rendering RORa inactive [15] . Staggerer mice exhibit severe cerebellar ataxia as well as a shortened period length when placed under constant dark conditions [20] . RORb À/À mice also exhibit aberrant circadian rhythm, such that under constant dark conditions RORb À/À mice have a longer 
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Trends in Endocrinology and Metabolism December 2012, Vol. 23, No. 12 period length than wild-type (wt) mice [17] . Although no overt circadian abnormalities were apparent in RORg À/À mice, recent work has demonstrated that RORg directly regulates neuronal PAS domain protein 2 (Npas2) in vivo suggesting a regulatory role for this receptor in Npas2dependent physiological processes [7, 24] . Likewise, several lines of evidence suggest a link between disrupted circadian rhythms and cardiovascular disease, metabolic disturbances, and mood disorders [25] . Given its extensive role in the regulation of the circadian rhythm, targeted modulation of RORa appears a feasible means by which to regulate these disorders.
RORs in metabolism and metabolic disease
The aforementioned genetic models have also been invaluable in identifying the roles of the RORs in physiological processes. On a normal diet, staggerer mice display hypoa-lipoproteinemia, have lower total plasma cholesterol levels, lower high-density lipoprotein (HDL), apolipoprotein AI (Apoa1, the major constituent of HDL), lower apolipoprotein CIII levels (Apoc3), Apoa2, and triglycerides, compared to wt mice [26] [27] [28] . Staggerer mice have decreased expression of the reverse cholesterol transporters Abca1 and Abca8/g1 in their liver and intestine, and are much less susceptible to hepatic steatosis and weight gain, compared to wt mice [29] . Sterol regulatory elementbinding protein 1, isoform c (Srebp-1c) is reduced in the liver and muscle of staggerer mice as is the enzyme fatty acid synthase (Fas) [29, 30] . Expression of the coactivators peroxisome proliferator-activated receptor-g coactivator (PGC)-1a and b, proteins involved in the regulation of oxidative metabolism and gluconeogenesis, are increased in staggerer mice [31] . Furthermore, expression of the P450 enzyme Cyp7b1 is reduced in staggerer mice. RORa directly regulates Cyp7b1 expression by binding to a functional RORE in the promoter regulatory region of the Cyp7b1 gene [30, 32] . These observations suggest that RORa functions as a positive regulator of Cyp7b1 function [30, 32] . Staggerer mice also have smaller brown and white adipose cells than wt mice and, when fed a high-fat diet, staggerer mice are resistant to weight gain and hepatic steatosis [29] . Evidence supporting a role for RORa in glucose metabolism derives from studies in steroid receptor coactivator-2 (SRC-2) knockout mice. These mice display symptoms similar to von Gierke's disease, which is associated with severe hypoglycemia and abnormal accumulation of glucose in the liver. SRC-2 controls the expression of hepatic glucose-6-phosphatase (G6Pase), an enzyme that is crucial for maintaining fasting blood sugar levels by increasing hepatic glucose production and coactivates RORa bound to the RORE on the G6Pase (G6PC) gene promoter [33] . Finally, it was recently demonstrated that RORa controls the expression and secretion of fibroblast growth factor 21 (FGF21), a hepatic hormone that regulates peripheral glucose tolerance and hepatic lipid metabolism [34] . Because RORa is crucial in regulating the expression of key enzymes in the gluconeogenic pathway, suppression of RORa activity may lead to a decrease in the elevated hepatic glucose-output levels observed in type 2 diabetes (T2D).
Initial characterization of RORg À/À mice revealed that they display normal cholesterol and triglyceride levels, but have slightly lower blood glucose levels than their wt counterparts [30] . However, recent evidence suggests that RORg may indeed have a role in metabolism through the regulation of adipogenesis and insulin sensitivity. Meissburger et al. demonstrate that RORg is a negative regulator of adipocyte differentiation in vitro. When overexpressed during adipocyte differentiation, RORg decreases the amount of differentiated adipocytes. However, in vivo differentiation of adipocyte precursors in RORg À/À mice was enhanced but showed decreased size. The smaller adipocytes were insulin sensitive and protected the mice from obesity-induced hyperglycemia and insulin resistance [35] . Moreover, analysis of adipose stromal-vascular fractions from obese human subjects demonstrated a positive correlation between RORg expression and adipocyte size that was negatively correlated with adipogenesis and insulin sensitivity. These findings suggest that RORg may be a novel target for the treatment of obesity-associated insulin resistance [35] .
Deletion of both RORa and RORg leads to similar changes in cholesterol, triglyceride, and blood glucose levels as in single-knockout mice. Gene expression analysis from livers of double-knockout (DKO) mice suggests a degree of functional redundancy between RORa and RORg which is most probably due to the similarities in RORE binding affinities [30] . However, the recent evidence regarding obesity and insulin resistance in the RORg À/À mice highlights the differences between the two NRs in metabolic processes.
RORs and (auto)immunity
Host defense against invading pathogens is largely dependent upon distinct adaptive immune responses facilitated by the differentiation of CD4 + T cells into specific lineages of effector T helper cells (T H 1, T H 2, and T H 17 cells) [36] . Both RORa and RORg, specifically RORgt, have generated significant attention over the past few years due to their essential role in the development of T H 17 cells. Until recently, it was generally thought that there were only two T helper subsets within the CD4 + T cell repertoire, T H 1 and T H 2. T H 1 cells mediated cellular immunity against intracellular bacteria and viruses whereas T H 2 cells were thought to be involved in the humoral response to parasitic pathogens [36] . However, T H 1 cells that respond to self-antigen can lead to autoimmune diseases whereas dysregulation of T H 2 responses to allergens and parasites can cause specific allergic and parasitic pathology. T H 1 cells had long been thought to be the mediators of tissue damage in autoimmune disease [36] . Key experiments using two established mouse models of autoimmunity, experimental autoimmune encephalomyelitis (EAE) and type II collagen-induced arthritis (CIA), largely led to the discovery of another T helper subset known as T H 17 cells ( Figure 2 ). In this setting, T H 17 cells were crucial mediators of much of the pathology associated with EAE and CIA. T H 17 cells are defined by a specific cytokine profile and secrete IL-17, IL-9, IL-21, IL-22, IL-26, and CCL20 [37] . These mediators are responsible for several different effector functions in host defense as well as in autoimmune diseases.
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Key factors in the development of T H 17 cells involve the RORs, specifically RORa and RORgt, one isoform of RORg that is exclusively detected in a few distinct types of cells in the immune system [39] . Overexpression of RORgt in naïve CD4 + T cells was demonstrated to drive the induction and development of T H 17 cells [40] . Furthermore, RORgt À/À mice display impaired T H 17 cell development [40] . Mice deficient in both RORa and RORg completely lack T H 17 cells and are resistant to the development of several autoimmune diseases, including EAE [41, 42] . Collectively, these data suggest that targeted inhibition of RORa and RORg with specific synthetic ligands could potentially provide a means for reducing autoimmune pathology.
Regulation of RORs by endogenous ligands
The ligand-binding domains of NRs are multifunctional. Typically, ligand binding induces a conformational change in the receptor resulting in dissociation of corepressors and recruitment of coactivators [1] . However, RORs are constitutively active -meaning that they are in an active conformation in the absence of ligand, and that ligand binding might actually repress receptor activity (inverse agonist; Box 1). Although identification of the endogenous ligands for RORs has been controversial, recent evidence suggests that, similarly to the liver X receptors (LXRs), oxygenated sterols may function as high-affinity ligands. Indeed, 7oxygenated sterols [7a-OHC (7a-hydroxycholesterol), 7b-OHC, and 7-ketocholesterol] function as inverse agonists for both RORs. The 7-oxygenated sterols bind to both RORa and RORg isoforms with a significantly greater affinity than do cholesterol and cholesterol sulfate, and suppress their transactivation properties. It was also shown that both RORa and RORg are constitutively active in the absence of ligand, and are able to bind coactivator peptides and activate transcription. Furthermore, the 7oxygenated sterols modulated the expression of RORa/gdependent target genes in a receptor-dependent manner [8] and were able to induce the conformational change necessary to alter cofactor binding and transcriptional activity, a core prerequisite for a bona fide ligand (Figure 3 ). Antagonist: an antagonist does not provoke a response from the receptor. Instead, an antagonist binds to the LBD and blocks the ability of an agonist to bind and activate the receptor.
Inverse agonist: an inverse agonist binds within the LBD of a given receptor, but inhibits the basal constitutive activity of the receptor. This generally describes a ligand for a particular NR that is not bound by any ligand in its basal conformation but is able to interact with a cofactor protein (either coactivator or corepressor), leading to constitutive transcriptional activity. An inverse agonist induces a conformational change within the receptor that decreases the affinity of the receptor for a cofactor protein and thereby represses transcription.
Partial agonists: partial agonists bind to and activate a receptor, but only with partial efficacy relative to a ligand that elicits a maximal response.
The RORs have intrinsic transcriptional activity, meaning that they are constitutively active, because it has been demonstrated that they bind coactivator proteins in the absence of ligand. Ligand binding represses the transcriptional activity of the receptor.
Review
Trends in Endocrinology and Metabolism December 2012, Vol. 23, No. 12 Several other endogenous RORa and RORg ligands have been described recently. 24S-hydroxycholesterol (24S-OHC) is a high-affinity ligand for RORa and RORg, and, similarly to the 7-oxygentated sterols, 24S-OHC acts as an inverse agonist and dose-dependently reduces RORa and RORg constitutive activity [43] . As a consequence, expression of BMAL1 and REV-ERBa mRNAs are also reduced. In a similar manner, 24S,25-epoxycholesterol (24,25-epoC) and 24R-cholesterol (24R-OHC) also selectively bind to and regulate the activity of RORg [43] .
20a-OHC, 22R-OHC, and 25-OHC were also shown to be putative endogenous ligands for RORg [44] because all three ligands dose-dependently increased the recruitment of coactivator peptides to RORg in vitro [44] . In addition, elucidation of the RORg crystal structure revealed that these three ligands bind to RORg in a similar manner. The RORg crystal structures also demonstrated that the AF-2 domain at the C terminus of the receptor, together with helices H3, H4, and H5, form a charge clamp pocket, the area that facilitates binding of coactivator proteins to NRs. Mutational studies of this region revealed that an intact charge clamp pocket was required for these hydroxycholesterols to affect RORg activity [44] (Table 1) .
Despite the identification of these putative ligands for the RORs, their physiological significance and whether they are regulatory or structural is not clear. For instance, several studies using RORa LBD purified from insect cells identified and characterized cholesterol, cholesterol sulfate, and several other cholesterol derivatives as endogenous putative ligands [45, 46] . Although subsequent studies have since established that several of these ligands are fortuitous, they suggest a requirement for ligandbound LBD for receptor stability [47] . Mutations in several key amino acids known to be involved in ligand binding abolishes the constitutive activity of the receptor, and this could be attributed to the instability of the receptor in the absence of ligand [48] . Furthermore, much of the work describing ROR ligands has been performed using artificial systems in vitro with luciferase reporter systems. To date, only the 7-oxygenated sterols and 24S-OHC, 24,25-epoC, and 24R-OHC were shown to affect ROR target gene expression in vitro [8, 43] . It is also difficult to envisage how many of these putative ligands could function as regulatory ligands given their abundance within tissues. Whether these ligands associate with the RORs in vivo has yet to be determined. These questions need to be answered to determine whether the described ROR ligands are deemed 'endogenous' and regulatory. With this in mind, the use of these ligands as 'tools' to understand the biology of the RORs should be met with caution. Despite some caveats, these data suggest that the RORs may function as lipid sensors and thus play a major role in the regulation of lipid metabolism.
Modulation of ROR activity with synthetic ligands
The identification of endogenous ligands to RORa and RORg intensified the search for synthetic ligands that could modulate ROR activity ( Table 1 ). The synthetic LXR agonist T0901317 was the first synthetic inverse agonist identified for both RORa and RORg. Despite its potency at activating RORa and RORg, T0901317 displays promiscuity and binds to several NRs including LXR, farnesoid X receptor (FXR), and pregnane X receptor (PXR), thus limiting its use as a chemical tool to explore the activity of the RORs in physiological settings [49, 50] .
A focused medicinal chemistry approach to develop analogs of T0901317 that activated RORs but not other NRs led to the development of several ROR-selective modulators. The first RORa/g-specific synthetic ligand characterized was the amide SR1078 ( Figure 3) . SR1078 was initially identified as an inverse agonist because it repressed the constitutive activity of RORa and RORg and inhibited the recruitment of coactivators to RORg in a dose-dependent manner [51] . However, further examination revealed that SR1078 acts as an agonist and stimulated expression of two ROR target genes, G6Pase and FGF21, in the liver. Pharmacokinetic studies revealed that SR1078 displays reasonable plasma exposure, thus enabling its use as a chemical tool to probe the function of RORa and RORg both in vitro and in vivo [51] . RORa expression is induced in response to some types of cellular stress and is downregulated in several breast, prostate, and ovarian cancer cell lines [52] . Interestingly, activation of RORa by SR1078 in this setting results in an increase in p53 levels and apoptosis, suggesting that RORa represents a novel target for the development of cancer therapeutics [53] .
The inverse agonist, SR3335 (Table 1) , was initially identified based on its ability to inhibit the constitutive activity of RORa. Furthermore, SR3335 bound directly to the LBD of RORa, with little effect at RORg, and suppressed expression of RORa target genes involved in hepatic gluconeogenesis -including G6Pase (GCPC) and phosphoenolpyruvate carboxykinase (PCK2). Pharmacokinetic studies revealed that SR3335 had reasonable plasma exposure and administration of this ligand to diet-induced obese (DIO) mice led to reduced plasma glucose levels following a pyruvate tolerance test (PTT), an indicator of gluconeogenesis [54] . Given that elevated glucose output is observed in T2D, suppression of RORa activity with novel ligands such as SR3335 may hold utility in the treatment of metabolic disorders, including T2D.
With the accumulating evidence surrounding the roles of RORa and RORgt role in T H 17 cell development and autoimmune pathology, identification of a dual and highly selective RORa/g inverse agonist that inhibits T H 17-mediated pathology is extremely enticing and such efforts led to the identification and characterization of SR1001 (Table 1) , a first-in-class RORa/g-specific inverse agonist (Figure 3 ). SR1001 binds directly to the LBD of both RORa and RORg, resulting in a conformational change that decreases affinity for coactivators and increased affinity for corepressors [55] . When screened against all 48 human nuclear receptors, SR1001 displayed activity only at RORa and RORg. In vitro, SR1001 inhibited IL-17 expression and T H 17 cell development without affecting the differentiation and function of any of the other T helper cell lineages [55] . More importantly, in vivo administration of SR1001 delayed the onset and severity of EAE through inhibition of T H 17 cell development and function. These data demonstrate that small-molecule inhibitors of ROR activity are effective at suppressing T H 17-mediated autoimmune diseases [55] .
Huh et al. identified the well-known cardiac glycoside digoxin (Table 1) , a small-molecule inhibitor of RORg activity. Currently, digoxin is used clinically in the treatment for various heart conditions. Digoxin normally competes with K + ions for the same binding site on the Na + /K + ATPase pump, thereby altering electrical conduction in the heart. Digoxin suppressed RORg-mediated activity only, and displayed no activity for RORa, Drosophila hormone receptor 3 (DHR3), the Caenorhabditis elegans nuclear hormone receptor Dauer formation-12 (DAF-12), or the androgen receptor [56] . Digoxin inhibited T H 17 cell differentiation and function and delayed the onset and severity of EAE [56] . Despite its efficacy in this model, major drawbacks with digoxin are its toxicity, the occurrence of adverse drug reactions associated with use of this drug, and a [58] . Ursolic acid, which is present in many plants, including apples, was originally described as a potential anticancer therapeutic able to inhibit various types of cancer cells by inhibiting STAT3 activation [59] . Further examination suggested that ursolic acid reduced the expression of matrix metalloproteinase-9 (MMP-9) potentially by acting through the glucocorticoid receptor (GR) [60] . Given the steroidal-like structures of both ursolic acid and digoxin, the possibility that both compounds exhibit activity at GR complicates the in vivo interpretations. Glucocorticoids are very effective at inhibiting symptoms of EAE and are in fact routinely prescribed by neurologists to reduce the severity and duration of relapses in MS patients.
Although SR1001 was effective at delaying the onset and reducing the severity of EAE, there was some concern that this compound, which modified the activity of RORa, would induce a phenotype similar to that of the staggerer mouse, including ataxia and a disrupted circadian rhythm [15, 55] . Furthermore, although several RORg selective modulators had already been described, their utility as candidates for further drug development was limited. Therefore, further development of RORg modulator was warranted. SR2211 is a selective RORg modulator that binds to the LBD of RORg and functions as an inverse agonist to suppress receptor activity [61] . Therefore, SR2211 is a potent and efficacious RORg modulator with potential utility in the treatment of T H 17-mediated autoimmune disorders.
Despite their high-profile roles in T H 17-mediated autoimmunity, RORgt and RORa expression is not restricted to this cell type, nor are all T H 17 cells pathogenic. Recent evidence links RORa to the maintenance of IgA + memory B cells [62] . Particular types of innate lymphoid cells, including lymphoid tissue inducer cells (LTi), gd T cells, and intestinal epithelial cells (IEPs), express RORgt [63, 64] . Innate lymphoid cells play important roles in tissue surveillance and can be the first line of defense against several invading pathogens [64] . Similarly, T H 17 cells have proved to be essential for host defense against some Gram-negative bacteria and fungal infections at mucosal surfaces [65] . Given the increasing number of immune cells expressing the RORs, inhibiting their activity during particular immune-system assaults may be detrimental. Therefore, careful assessment of the infection and invading pathogen(s) may be warranted before administration. Alternatively, the control of some infections due to specific Gram-negative bacteria or fungi could exploit ROR agonists to amplify the immune response from these ROR-restricted cell types.
Concluding remarks
To date, several groups have developed or described numerous small-molecule ligands for RORa and RORg. Collectively, these data demonstrate that these orphan NRs are not only valid drug targets, but have efficacy at suppressing T H 17 cell development and function both in vitro and in vivo. Although further optimization of the small molecules is still needed, it is obvious that targeting the RORs for the treatment of T H 17-mediated autoimmune disorders represents a promising endeavor. Current treatments for known T H 17-mediated autoimmune diseases, including multiple sclerosis, use agents that are general immunosuppressants, and thus the side-effect profile is significant. Targeting of the RORs presents a significant advantage over the current therapies because they specifically target the one arm of the immune system that mediates disease instead of the immune system as a whole. Finally, extensive analysis of the use of these ligands in vivo has yet to be carried out. Although genetic studies are valuable tools for elucidating the roles these receptors play in physiology, the roles of the RORs during metabolic and autoimmune disease progression can be extensively studied through in vivo use of specific synthetic ligands.
